Verastem Oncology licenses VS-7375 rights from GenFleet Therapeutics, aiming to target KRAS-driven cancers. Early Phase I ...
Mabwell Bioscience plans a secondary listing in Hong Kong to bolster development and global expansion. The move targets Hong ...
Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million ...
Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...
US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS ...
German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi ...
German biotech BioNTech is today presenting its 2025 strategic priorities and progress on the company’s pipeline of mRNA ...
Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...
The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...
The NIH introduces a policy requiring drugmakers using its patents to submit affordability plans, addressing concerns over ...
US genetic medicines company Scribe, which is seeking to unlock the potential of CRISPR to transform human health, announced ...
Jiangsu Hengrui and Kailera reveal Phase II data for HRS9531, a GLP-1/GIP dual agonist showing 21.1% placebo-adjusted weight ...